Peripheral Nerve Stimulation in Diabetic Patients

NCT01488474 | Completed

• 1 other identifier: KLI 135
• Study Type: observational
• Target: 124
• Locations: 1 country
• Sites: 1

Brief Summary

The prevalence of diabetes mellitus (DM) in industrialized countries is estimated to be about 7.3% and its incidence has been growing in recent years. The prevalence of diabetic neuropathy in the diabetic patient population is up to 50%. When limb surgery is necessary, it is reasonable to assume that diabetic patients will benefit from a peripheral regional anesthesia because of the severe comorbidities associated with DM. On the other hand, the use of regional anesthesia (RA) has generally not been recommended in patients with preexisting neuropathies mainly because of medical liability issues, as worsening neuropathy could be attributed to nerve damage caused by the regional anesthetic. The current state of the art of peripheral regional anesthesia for the identification of correct placement of an injection needle suitably close to the target nerve is to elicit a motor response by current injection through the needle. Constant reduction of the current as the nerve is approached ensures close proximity so that an effective nerve block is obtained when the local anesthetic is delivered through the needle, and absence of a motor response at 0.3 mA is generally accepted as a safety marker to avoid harmful intraneural injection. An important deficit in our understanding is whether diabetic neuropathy influences the stimulation parameters for peripheral nerve stimulation (PNS), possibly decreasing safety. The currently proposed research is guided by the hypothesis that nerves in patients with DM are more resistant to stimulation and the current thresholds for PNS have to be set much higher to prevent injections from occurring within the epineurium. The investigators will examine the effect of DM on nerve excitability in a blinded, prospective, observational case control trial. Accordingly, the investigators have defined following aims: Specific Aim 1: To characterize the required stimulation current in patients with and without diabetes mellitus. Specific Aim 2: Follow-up to examine if the rate of adverse neurologic events is higher in diabetic patients. Specific Aim 3: Guided by the results, formulate recommendations for the performance of regional anesthesia in patients with a history of DM. These experiments will provide better understanding of the needle-current-nerve relationship during peripheral nerve stimulation. Findings from this study will have a major impact on patient safety, especially in the subgroup with preexisting neuropathy, undergoing regional anesthesia.

Conditions

Diabetic Polyneuropathy

Keywords

regional anesthesia; peripheral nerve stimulation; diabetes; diabetic neuropathy

Outcome Measures

Primary Outcomes (1)

• Minimal current threshold for distal motor response at needle tip nerve contact

  18 months

Study Arms (2)

Diabetes Mellitus (DM)

Patients with diagnosed diabetes mellitus type 1 or 2 undergoing surgery of the lower limb and are receiving regional anesthesia with peripheral nerve stimulation

Procedure: peripheral nerve stimulation

Control (C)

Patients with no history of diabetes mellitus Type 1 or 2 undergoing surgery of the lower limb and are receiving regional anesthesia with peripheral nerve stimulation

Procedure: peripheral nerve stimulation

Interventions

peripheral nerve stimulation PROCEDURE

defining the minimal current threshold for distal motor response

Control (C); Diabetes Mellitus (DM)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Surgical patients scheduled for lower limb surgery and are eligible for a popliteal sciatic nerve block

You may qualify if:

• Patients of both sexes
• age more than 18 years
• American Society of Anesthesiology status 1 to 4
• signed informed consent

You may not qualify if:

• Pregnancy
• Allergies to local anesthetics
• Unwillingness or incapability to sign informed consent
• Any preexisting neurological deficit of the lower limb that cannot be attributed to diabetic neuropathy
• Ongoing dual anti-platelet therapy

Sponsors & Collaborators

• Medical University of Graz: lead

Study Sites (1)

Medical University of Graz

Graz, 8036, Austria

Location

Related Publications (1)

• Heschl S, Hallmann B, Zilke T, Gemes G, Schoerghuber M, Auer-Grumbach M, Quehenberger F, Lirk P, Hogan Q, Rigaud M. Diabetic neuropathy increases stimulation threshold during popliteal sciatic nerve block. Br J Anaesth. 2016 Apr;116(4):538-45. doi: 10.1093/bja/aew027.

  PMID: 26994231 DERIVED

Biospecimen

Retention: SAMPLES WITH DNA

* blood samples * any material from surgical resections

MeSH Terms

Conditions

Diabetic Neuropathies; Diabetes Mellitus

Condition Hierarchy (Ancestors)

Peripheral Nervous System Diseases; Neuromuscular Diseases; Nervous System Diseases; Diabetes Complications; Endocrine System Diseases; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Officials

• Marcel Rigaud, PD, MD

  Medical University of Graz

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: December 2, 2011
• First Posted: December 8, 2011
• Study Start: January 1, 2012
• Primary Completion: December 1, 2013
• Study Completion: December 1, 2013
• Last Updated: January 30, 2015

Record last verified: 2015-01

Locations

AU (1)